Die Inhalte stammen aus dem NEJM Journal Watch Oncology & Hematology, der von der NEJM Group, a Division of the Massachusetts Medical Society, hergestellt und veröffentlich wird. Alle Rechte sind vorbehalten und alle Inhalte sind urheberrechtlich geschützt. Universimed und unsere Sponsoren ermöglichen Ihnen den Zugang zu diesen Inhalten als professionelle Unterstützung.
Adagrasib Induces Response in KRASG12C-Mutated NSCLC
Over 40% of patients had an objective response, and adagrasib showed activity against CNS metastases in some.
Targeted T-Cell Therapy for Metastatic Pancreatic Cancer: A Case Report
A patient treated with autologous engineered T cells had partial regression of lung metastases.
Outpatient Venous Thromboembolism Prophylaxis for Patients with COVID-19
Enoxaparin prophylaxis did not result in a decrease in hospitalization or death.
A New Treatment Option for Unresectable Hepatocellular Carcinoma
The combination of an anti-CTLA-4 agent and an anti-PDL-1 agent improved survival compared to sorafenib.
Immunotherapy for HER2-Positive Breast Cancer?
The addition of a checkpoint inhibitor to chemotherapy did not increase rates of pathologic complete response.
ASCO 2022 Meeting Report — Hematologic Malignancies
Key trials in treatment and management of a variety of hematologic malignancies.
Oral Therapy for Chronic Lymphocytic Leukemia in Older Patients and Those with Comorbidities
Frontline ibrutinib plus venetoclax outperformed chlorambucil plus obinutuzumab for depth and duration of response but was associated with more cardiovascular toxicities.
Risks of Steroid Use in Patients with Sickle Cell Disease
Exposure to systemic steroids was associated with a fourfold increased risk for hospitalization for a vaso-occlusive episode.
Addition of Durvalumab to First-Line Chemotherapy in Advanced Biliary Cancer
Survival outcomes were significantly improved with durvalumab compared with placebo.